Inohana Campus of Chiba University: the only campus among Japanese universities that accommodates three distinct medical faculties of Medicine, Pharmaceutical Sciences, and Nursing as well as the University Hospital.

亥鼻キャンパス航空写真2013 (2).JPG

■Development of “Preventive Vaccine Against Infectious Diseases, Allergy, and Cancers.”

The universally prevalent emerging and re-emerging infectious diseases including Ebola, new strains of influenza, or AIDS, or allergies such as asthma, hay fever, and food allergies develop mainly in mucosal tissues in the mouth, digestive organs, respiratory organs, or genitals. Currently, there has been growing interest in studies to understand and control the immune system of mucosal surfaces so that we can prevent and treat these diseases.
Existing injectable vaccines are able to prevent serious conditions, but are not effective enough to defend against infection. Our project has the potential to generate a ”Preventive Vaccine,” which can boost immunity of the body to block the transmission of infectious agents at the entrance of these agents, mucous membrane. This will be the world first Next-generation Vaccine.

■About a Joint Research Center


In April 2016, Chiba University launched the Mucosal Immunity and Allergy Therapeutics Research Center jointly at the Inohana Campus(Chiba Research Center)and UCSD School of Medicine(San Diego Research Center).
UCSD is one of the top universities, which produces many Nobel Prize winners. UCSD stands as an academic powerhouse in the fields of Immunology, Systematic Biology, Metabolomics, and Natural Products Chemistry; it also delivers exceptional achievements in basic Allergology research.

Structure of Joint Research Center


Hiroshi NAKAJIMA, Professor of Department of Allergy and Clinical Immunology,

Graduate School of Medicine, Chiba University